Stock Buzzer: What’s Propelling Zynerba Pharmaceuticals Inc to Decline So Much?

Stock Buzzer: What's Propelling Zynerba Pharmaceuticals Inc to Decline So Much?

The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is a huge mover today! About 417,935 shares traded hands or 80.28% up from the average. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has risen 58.09% since April 18, 2016 and is uptrending. It has outperformed by 53.66% the S&P500.
The move comes after 5 months negative chart setup for the $179.10M company. It was reported on Nov, 18 by Barchart.com. We have $13.49 PT which if reached, will make NASDAQ:ZYNE worth $23.28 million less.

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Ratings Coverage

Out of 5 analysts covering Zynerba Pharmaceuticals (NASDAQ:ZYNE), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Zynerba Pharmaceuticals has been the topic of 7 analyst reports since August 31, 2015 according to StockzIntelligence Inc. Jefferies initiated the stock with “Buy” rating in Monday, August 31 report. The company was initiated on Tuesday, September 8 by Oppenheimer. The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) earned “Overweight” rating by Piper Jaffray on Monday, August 31. Oppenheimer maintained Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) rating on Thursday, November 12. Oppenheimer has “Outperform” rating and $34 price target. The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) earned “Buy” rating by Canaccord Genuity on Monday, September 14. On Friday, October 7 the stock rating was initiated by H.C. Wainwright with “Buy”.

According to Zacks Investment Research, “Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania.”

Another recent and important Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) news was published by Marketwatch.com which published an article titled: “/quotes/zigman/3870025/realtime” on July 03, 2015.

ZYNE Company Profile

Zynerba Pharmaceuticals, Inc., incorporated on January 31, 2007, is a specialty pharmaceutical firm focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Firm is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment